Hives News and Research

RSS

Hives (or Urticaria) are a kind of skin rash notable for dark red, raised, itchy bumps. Hives are frequently caused by allergic reactions; however, there are many non-allergic causes.

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Amedra Pharmaceuticals LLC has announced re-launch of Adrenaclick®, a single-dose epinephrine auto-injector, for the emergency treatment of life threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Adrenaclick® will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths.

15 Jun 2013

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick by Amedra Pharmaceuticals LLC, for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.

15 Jun 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

21 Mar 2013

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

Two million Americans are allergic to insect stings, an allergy which sends more than 500,000 people to the emergency room annually. Yet, according to a study published today in the March issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAA), while fire ant allergy sufferers know allergy shots can save their life, more than 60 percent do not adhere to treatment guidelines.

4 Mar 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

29 Jan 2013

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

14 Dec 2012

Novel tactile conditioning experiment using honey bees

Honey bees are a highly organized, social species, as demonstrated by their complex colonies and the geometric structure of their hives. For hive building, the honey bee strongly relies on its tactile sense, and a new video-article in JoVE (Journal of Visualized Experiments) illustrates a novel tactile conditioning experiment using honey bees.

13 Dec 2012

Allergy Centre of the Charité-Universitätsmedizin Berlin to host three international scientific conferences

The Allergy Centre of the Charité-Universitätsmedizin Berlin will host three international scientific conferences in the upcoming week. According to Prof. Marcus Maurer, Associate Director of the Allergy Centre at the Clinic for Dermatology, Venereology and Allergology: "Allergological issues have been gaining in importance among clinical physicians." Prof. Mauer explains that all three conferences are focused on enabling scientific exchange about basic allergy research: "Our intent is to offer clinical physicians the opportunity to learn something about the cells, the basis for allergological illnesses.

23 Nov 2012

General guidelines to understand allergic skin conditions

Winter months can bring on the itch as cold weather and indoor heat dry out the skin. It's possible, suggests Chicago allergist, Brian Rotskoff, MD of Clarity Allergy Center, that your winter itch could be caused by more than just the weather. For some people itchy, dry skin is just that, but for others it can be a symptom of atopic dermatitis (eczema), contact dermatitis, or hives (urticaria).

16 Nov 2012

Leading allergy organizations release report that sheds light on angioedema

With today's modern medicine, misdiagnoses may be unexpected and surprising. But when symptoms of an unknown and uncommon illness mimic a number of other conditions, it can be difficult for medical professionals to properly diagnose and treat patients. That's why four leading allergy/immunology organizations have announced the release of a report to help set a new standard for a commonly misdiagnosed, under-recognized and under treated condition known as angioedema, the rapid swelling of deep layers of skin and tissue.

9 Nov 2012

Lone star tick causes alpha-gal meat sensitivity in regional population

Meat lovers living in the central and southern regions of the country might be opting for a vegetarian lifestyle if meat comes with an unwanted side of a life-threatening allergic reaction. According to a study presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), the lone star tick inhabiting these regions is the primary reason for what's known as a meat induced alpha-gal allergic reaction.